Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

Sponsor: Matthias Griese

NCT ID: NCT02852928

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Not specified by the sponsor
How long the study runs
Study runs about 192 months (dates as stated)
About the drug or intervention
Not specified by the sponsor
Patient visit burden
Not specified by the sponsor

In plain English

This European study collects information and samples (a register and biobank) about childhood interstitial lung disease (chILD) — a group of rare lung conditions in children that cause breathing problems. The aim is to learn more about these rare diseases to improve how they are understood and managed.

Who can take part

  • Children with a suspected or confirmed diagnosis of interstitial lung disease (ILD)
  • Children whose illness looks like ILD but is not yet confirmed
  • Children with rare lung diseases affecting specific parts of the lung

Who may not be able to

  • Children who do not meet the inclusion criteria

What taking part involves

  • • Not stated — ask the trial team

Time commitment: Not stated — ask the trial team about visits, duration, and what taking part involves.

Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.

Type of study
Observing health over time
Ages
Not specified
Who
All
Number of participants
1,000
Started
2013-12
Last checked
2022-09

Plain English Summary

What is this study?

  • • Testing a new treatment for lung diseases, interstitial
  • • Clinical study - 1,000 participants
  • • Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes

Who can take part?

  • • Adults
  • • Diagnosed with lung diseases, interstitial

Where?

  • • Edinburgh - University of Edinburgh

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes

More detail

Objective 1: Generation of a common European database and biobank. The existing national programmes to collect data on chILD in three countries (France, Germany, UK) will enable the consortium to swiftly adapt current frameworks to a functionally appropriate pan-European web-based database and biobank. Importantly, compatibility with ongoing United States chILD data base developments will be factored in. Objective 2: Continuous assessment and implementation of guidelines and treatment protocols. Our Standards Working Group will convene regularly. Initial tasks will establish (a) specific diagnostic pathways, including detailed protocols for gathering clinical information, blood testing, imaging and pathology ("Best Practice Checklist"); (b) international panels of clinicians, geneticists, radiologists and pathologists who will review every diagnosis to quality control the data; and (c) detailed protocols for follow up to generate natural history data. Objective 3: Recruitment of a carefully characterized cohort of chILD patients. European wide recruitment and interdisciplinary critical peer review of all diagnoses submitted from across Europe is imperative. Each case will be given a diagnosis independently; if no firm diagnosis is possible, we will review the case periodically as new information becomes available. During the first year of the study, clinicians´ decisions according to local practice and outcomes will be independently monitored and assessed. Objective 4: Determine the value of outcomes used in chILD. We will systematically optimize and clarify the relative weight of a large spectrum of single and composite clinical outcomes (using both clinician and carer scoring), sequential limited chest CT (to minimise radiation exposure), lung function testing, histopathological categorization of lung biopsies, serum markers and genetic tests. Variability, reproducibility and the effects of training on reading images will be investigated. Objective 5: Assess treatment variations used, deliver data from defined protocols and linked outcomes. This project will analyse in detail treatment and outcomes within and between subjects using data collected. Analysis of the collected data will enable us to support the definition of trial protocols planned in the future.

Lung Diseases, InterstitialPulmonary Alveolar ProteinosisPulmonary EosinophiliaPulmonary FibrosisRespiratory Distress Syndrome, NewbornChild

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: Not specified
  • Who can join: All genders

What the study is looking for

  • ✓all children with suspected or
  • ✓verified diagnosis of ILD or
  • ✓masquerading as ILD and
  • ✓those with rare localized parenchymal lung diseases

Who cannot take part

  • ✗other indication as inclusion criteria
See the full criteria
Inclusion Criteria: * all children with suspected or * verified diagnosis of ILD or * masquerading as ILD and * those with rare localized parenchymal lung diseases Exclusion Criteria: * other indication as inclusion criteria

Where Is This Study? (1 UK site)

University of Edinburgh

Edinburgh EH4 2XU, United Kingdom

Recruiting
Site contact (verified)

How to Get in Touch

Matthias Griese, Prof.

Sponsor contact

CONTACT

+49/89/440057871 Matthias.Griese@med.uni-muenchen.de

Katarzyna Michel, Dr. med.

Sponsor contact

CONTACT

+49/89/440057878 Katarzyna.Michel@med.uni-muenchen.de
Data sourced from ClinicalTrials.gov · Last verified: 2022-09